Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNXP Stock Price Chart Interactive Chart >
TNXP Price/Volume Stats
| Current price | $0.37 | 52-week high | $14.24 |
| Prev. close | $0.37 | 52-week low | $0.36 |
| Day low | $0.37 | Volume | 966,600 |
| Day high | $0.38 | Avg. volume | 4,012,121 |
| 50-day MA | $0.46 | Dividend yield | N/A |
| 200-day MA | $2.56 | Market Cap | 21.57M |
Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio
Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").
Latest TNXP News From Around the Web
Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.
TNXP: Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Up to Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has built a diverse pipeline that includes development candidates for multiple central nervous system (CNS) diseases, biodefense, and immunology. The company could have up to six Phase 2 |
Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in AnimalsHematopoietic Stem Cell Transplantation (HCT) from Unrelated Donors is a Component of the Treatment Protocol for Several Hematologic Malignancies GvHD Complicates Treatment and Limits the Success of Engraftment after HCT In addition to GvHD, Tonix is Developing TNX-1500 for Prophylaxis of Organ Transplant Rejection and Treatment of Autoimmune Disorders Phase 1 Study of TNX-1500 is Expected to Start in First Half 2023 CHATHAM, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding |
Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy CongressTNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabilities for Biologics CHATHAM, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chie |
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral CongressResearch Being Conducted in Collaboration with Scientists at Columbia University SARS-CoV-2 Variants have Evaded Antibody Therapeutics Previously Granted FDA Emergency Use Authorization, but which are No Longer Recommended for Use by the NIH COVID-19 Guidelines Panel Immunocompromised Individuals, Including Organ Transplant Recipients, are at Increased Risk of Severe COVID-19 and Poor Outcomes Therapeutic Antibody Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabi |
Tonix Pharmaceuticals to Participate in the A.G.P. Biotech ConferenceCHATHAM, N.J., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate virtually in the A.G.P. Biotech Conference and host investor meetings. The conference is being held Wednesday, November 30, 2022 – Thursday, December 1, 2022. Investors interested in arranging a meeting with the Company’s management during the conference should contact the conference coordinator or Ian Fr |
TNXP Price Returns
| 1-mo | -19.02% |
| 3-mo | -63.37% |
| 6-mo | -80.83% |
| 1-year | -97.41% |
| 3-year | -98.81% |
| 5-year | -100.00% |
| YTD | -96.77% |
| 2021 | -47.01% |
| 2020 | -42.31% |
| 2019 | -94.68% |
| 2018 | -93.62% |
| 2017 | -26.60% |
Loading social stream, please wait...